Membrane Fusion Inhibition, Immune Modulation, and Cholesterol Synthesis Dysregulation During Dengue Virus Inhibition by 25-Hydroxycholesterol

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated deep summary by claude@2026-06, 2026-06-24 · read from full text

The paper investigated how 25-hydroxycholesterol (25-HC) inhibits dengue virus infection, focusing on host membrane fusion, cholesterol metabolism, lipid raft organization, and immune signaling. Using mechanistic studies and transcriptomic analyses, the authors found that 25-HC disrupts DENV envelope (E)-protein binding and viral membrane fusion by altering cholesterol distribution, suppresses cholesterol biosynthesis pathways required for viral replication while increasing lipid droplet formation and stress-response pathways, and primes innate immune responses including NLRP3 inflammasome and MAPK signaling with selective interferon-stimulated gene modulation. The authors also reported synergistic antiviral effects of 25-HC when combined with direct-acting antivirals such as Remdesivir. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 1,957 characters · extracted from oa-doi-fallback · click to expand
Abstract Physicochemical properties and composition of cellular membranes are crucial for regulating broad cellular responses including signaling and defense against pathogens. Dengue virus (DENV) exploits cholesterol-rich membranes and host lipid pathways, such as cholesterol biosynthesis, lipid raft organization, and lipid droplet formation, for entry, replication, and assembly. Additionally, lipid-based plasma membrane signaling can trigger innate immune responses that attenuate viral growth, underscoring the dual role of lipids in facilitating and restricting DENV infection. Here, we demonstrate that 25-hydroxycholesterol (25-HC), an oxidized cholesterol metabolite, inhibits DENV infection through a multifaceted mechanism. 25-HC disrupts viral membrane fusion by altering cholesterol distribution and lipid raft organization, impairing the binding and fusion of the DENV envelope (E) protein with host membranes. Additionally, 25-HC modulates host cholesterol metabolism by suppressing biosynthesis pathways essential for viral replication while enhancing lipid droplet formation and stress-response pathways. Transcriptomic analyses reveal that 25-HC primes innate immune responses, activating proinflammatory pathways such as the NLRP3 inflammasome and MAPK signaling, while selectively modulating interferon-stimulated gene expression. Notably, 25-HC exhibits synergistic antiviral effects when combined with direct-acting antivirals like Remdesivir, underscoring its potential in combination therapies. These findings establish 25-HC as a promising candidate for host-directed antiviral strategies against DENV and other enveloped viruses. Competing Interest Statement The authors have declared no competing interest. Footnotes ↵7 Lead contact This version of the manuscript includes details of lipid droplet generation by 25-HC, membrane cholesterol distribution inferring how membrane accessible cholesterol accumulate in lipid droplets.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00